Clinical trial perspective for adult and juvenile Huntington′s disease using genetically-engineered mesenchymal stem cells
Progress to date from our group and others indicate that using genetically-engineered mesenchymal stem cells (MSC) to secrete brain-derived neurotrophic factor (BDNF) supports our plan to submit an Investigational New Drug application to the Food and Drug Administration for the future planned Phase...
Main Authors: | Peter Deng, Audrey Torrest, Kari Pollock, Heather Dahlenburg, Geralyn Annett, Jan A Nolta, Kyle D Fink |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Neural Regeneration Research |
Subjects: | |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=5;spage=702;epage=705;aulast=Deng |
Similar Items
-
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
by: Robert D. Wyse, et al.
Published: (2014-01-01) -
Use of Genetically Altered Stem Cells for the Treatment of Huntington’s Disease
by: Andrew T. Crane, et al.
Published: (2014-03-01) -
A novel Huntington's disease mouse model to assess the role of neuroinflammation on disease progression and to develop human cell therapies
by: Heather Dahlenburg, et al.
Published: (2021-07-01) -
Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients
by: Ashley Gutierrez, et al.
Published: (2020-01-01) -
ESC-Derived BDNF-Overexpressing Neural Progenitors Differentially Promote Recovery in Huntington's Disease Models by Enhanced Striatal Differentiation
by: Tina Zimmermann, et al.
Published: (2016-10-01)